Posted by Michael Wonder on 16 Oct 2019
Bill to create CMS star ratings program for biosimilars introduced in House
16 October 2019 - The bipartisan bill would require HHS to evaluate Medicare Advantage (MA) plans based on whether biosimilars are available to enrollees.
Representatives Paul Tonko, D-New York, and Rob Gibbs, R-Ohio, have introduced H.R. 4629, the Star Ratings for Biosimilars Act, in the House. The bipartisan bill would require HHS to evaluate Medicare Advantage (MA) plans based on whether biosimilars are available to enrollees.
Under the proposed legislation, which would amend title 18 of the Social Security Act, starting in 2021, HHS would add a new set of measures to the current 5-star rating system based on biosimilar access in Part B and, for MA plans that offer prescription drug coverage, in Part D.
